Glenn Mattes, the CEO of TFF Pharmaceuticals discusses the company's hybrid business model consisting of developing an internal portfolio of products and also working with external partners to apply thin film freezing technology.
The company's first compound is tacrolimus, an antifungal being developed for treating invasive pulmonary aspergillosis and lung transplant patients. Other compounds are targeting COVID-19.
Glenn says, "So our thin film freezing technology has the ability to transform pharmaceutical products, mostly solid pharmaceutical products, into dry powder formulations. One characteristic that is common to most pharmaceutical compounds is that they're rather poorly water absorbed. So when they are made into a drug, the ability to get enough product into the bloodstream or the plasma means you have to dose the compound at a pretty high level, and you butt up against sort of the adverse events profile."
"So, by using thin film freezing, you ultimately can lead to a lower dose of the drug being administered directly to the lung. Therefore you have the opportunity to improve on the efficacy and safety profile of the product that you're working on."